Literature DB >> 23271778

Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting.

Lars Holmberg1, Anna Bill-Axelson, Gunnar Steineck, Hans Garmo, Juni Palmgren, Eva Johansson, Hans-Olov Adami, Jan-Erik Johansson.   

Abstract

In the Scandinavian Prostate Cancer Group Trial Number 4 (SPCG-4), 347 men were randomly assigned to radical prostatectomy and 348 to watchful waiting. In the most recent analysis (median follow-up time = 12.8 years), the cumulative mortality curves had been stable over the follow-up. At 15 years, the absolute risk reduction of dying from prostate cancer was 6.1% following randomization to radical prostatectomy, compared with watchful waiting. Hence, 17 need to be randomized to operation to avert one death. Data on self-reported symptoms, stress from symptoms, and quality of life were collected at 4 and 12.2 years of median follow-up. These questionnaire studies show an intricate pattern of symptoms evolving after surgery, hormonal treatments, signs of tumor progression, and also from natural aging. This article discusses some of the main findings of the SPCG-4 study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271778      PMCID: PMC3540876          DOI: 10.1093/jncimonographs/lgs025

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  10 in total

1.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

Review 2.  Prognostic markers under watchful waiting and radical prostatectomy.

Authors:  Lars Holmberg; Anna Bill-Axelson; Hans Garmo; Juni Palmgren; Bo Johan Norlén; Hans Olov Adami; Jan Erik Johansson
Journal:  Hematol Oncol Clin North Am       Date:  2006-08       Impact factor: 3.722

3.  Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4).

Authors:  Swen-Olof Andersson; Ove Andrén; Johan Lyth; Jennifer R Stark; Martin Henriksson; Hans-Olov Adami; Per Carlsson; Jan-Erik Johansson
Journal:  Scand J Urol Nephrol       Date:  2011-01-25

4.  Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

Authors:  Eva Johansson; Gunnar Steineck; Lars Holmberg; Jan-Erik Johansson; Tommy Nyberg; Mirja Ruutu; Anna Bill-Axelson
Journal:  Lancet Oncol       Date:  2011-08-05       Impact factor: 41.316

5.  Prostate-specific antigen levels as a predictor of lethal prostate cancer.

Authors:  Katja Fall; Hans Garmo; Ove Andrén; Anna Bill-Axelson; Jan Adolfsson; Hans-Olov Adami; Jan-Erik Johansson; Lars Holmberg
Journal:  J Natl Cancer Inst       Date:  2007-04-04       Impact factor: 13.506

6.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Hans Garmo; Jennifer R Stark; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

7.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer.

Authors:  Lars Holmberg; Anna Bill-Axelson; Fred Helgesen; Jaakko O Salo; Per Folmerz; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Christer Busch; Steg Nordling; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson; Bo Johan Norlén
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

8.  Quality of life after radical prostatectomy or watchful waiting.

Authors:  Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg
Journal:  N Engl J Med       Date:  2002-09-12       Impact factor: 91.245

9.  Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.

Authors:  Eva Johansson; Anna Bill-Axelson; Lars Holmberg; Erik Onelöv; Jan-Erik Johansson; Gunnar Steineck
Journal:  Eur Urol       Date:  2008-09-02       Impact factor: 20.096

10.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

  10 in total
  16 in total

Review 1.  Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Authors:  Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

2.  Radical prostatectomy versus deferred treatment for localised prostate cancer.

Authors:  Robin Wm Vernooij; Michelle Lancee; Anne Cleves; Philipp Dahm; Chris H Bangma; Katja Kh Aben
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

3.  Toward ethically responsible choice architecture in prostate cancer treatment decision-making.

Authors:  J S Blumenthal-Barby; Denise Lee; Robert J Volk
Journal:  CA Cancer J Clin       Date:  2015-05-21       Impact factor: 508.702

4.  [PREFERE--open questions].

Authors:  C Schäfer; L Weißbach
Journal:  Urologe A       Date:  2014-03       Impact factor: 0.639

5.  Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.

Authors:  Jane M Lange; Aaron A Laviana; David F Penson; Daniel W Lin; Anna Bill-Axelson; Sigrid V Carlsson; Lisa F Newcomb; Bruce J Trock; H Ballentine Carter; Peter R Carroll; Mathew R Cooperberg; Janet E Cowan; Laurence H Klotz; Ruth B Etzioni
Journal:  Cancer       Date:  2019-10-22       Impact factor: 6.860

6.  [Effects of modified inclusion criteria and negative reporting about PSA screening on the number of potentially recruitable patients for the PREFERE study].

Authors:  J Mathes; M Burger; J E Gschwend; O W Hakenberg; S Krege; J Lehmann; K Miller; J Roigas; S Roth; T Kälble
Journal:  Urologe A       Date:  2016-09       Impact factor: 0.639

7.  Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.

Authors:  Andreas G Wibmer; Ines Nikolovski; Joshua Chaim; Yulia Lakhman; Robert A Lefkowitz; Evis Sala; Sigrid V Carlsson; Samson W Fine; Michael W Kattan; Hedvig Hricak; Hebert Alberto Vargas
Journal:  Radiology       Date:  2021-12-21       Impact factor: 11.105

8.  [Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].

Authors:  T Reinhold; C Dornquast; C Börgermann; L Weißbach
Journal:  Urologe A       Date:  2016-12       Impact factor: 0.639

9.  Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer.

Authors:  Jessika A Contreras; Richard B Wilder; Eric A Mellon; Tobin J Strom; Daniel C Fernandez; Matthew C Biagioli
Journal:  Int Braz J Urol       Date:  2015 Jan-Feb       Impact factor: 1.541

10.  Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Authors:  E L Turner; C Metcalfe; J L Donovan; S Noble; J A C Sterne; J A Lane; K N Avery; L Down; E Walsh; M Davis; Y Ben-Shlomo; S E Oliver; S Evans; P Brindle; N J Williams; L J Hughes; E M Hill; C Davies; S Y Ng; D E Neal; F C Hamdy; R M Martin
Journal:  Br J Cancer       Date:  2014-05-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.